
CLAIMS

1. Compounds of the general formula **(I)**




(I)


wherein the single elements T or P are connected in either direction from the carbonyl (C=O) point of attachment to the nitrogen (N) of the next element and wherein

– either


T^1 is an α amino acid residue of one of the formulae



AA1 AA2 AA3 AA4




AA5 AA6 AA7




AA8 AA9 AA10

and

~~T^2 is an α-amino acid residue of one of the formulae~~




AA11 AA12 AA13 AA14




AA15 AA16 AA17

– or

T^1 is an α-amino acid residue of one of the formulae




AA18 AA19 AA20




AA21 AA22 AA23

and


T^2 is an α-amino acid residue of one of the formulae AA11 to AA17, hereinabove, or an α-amino acid residue of one of the formulae



AA24 AA25 AA26



AA27 AA28 AA29




AA30 AA31 AA32

P^1, P^3 and P^4 are independently

-$NR^1CH(R^{29})CO$-; -$NR^1CH(R^{30})CO$-; or -$NR^1CH(R^{31})CO$-;

P^2 is an α-amino acid residue of one of the formulae



AA33 AA34

A is O; NR^{17}; S; SO; or SO_2;

X is OH; NH_2; OR^{16}; NR^1R^{16}; or $NR^{17}R^{18}$;

Y is NH_2; F; OR^{16}; NR^1R^{16}; or $NR^{17}R^{18}$;

R^1, R^2 and R^3 are independently

H; CF_3; lower alkyl; lower alkenyl; aryl-lower alkyl; or heteroaryl-lower alkyl;

R^4, R^5, R^6, R^7 and R^8 are independently

H; F; CF_3; lower alkyl; lower alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; $-(CHR^{15})_oOR^{17}$; $-(CHR^{15})_oSR^{17}$; $-(CHR^{15})_oNR^{17}R^{18}$; $-(CHR^{15})_oOCONR^{17}R^{18}$; $-(CHR^{15})_oNR^1CONR^{17}R^{18}$; $-(CHR^{15})_oNR^1COR^{17}$; $-(CHR^{15})_oCOOR^{17}$; $-(CHR^{15})_oCONR^{17}R^{18}$; $-(CHR^{15})_oPO(OR^1)_2$; $-(CHR^{15})_oSO_2R^{17}$; $-(CHR^{15})_oNR^1SO_2R^{17}$; $-(CHR^{15})_oSO_2NR^{17}R^{18}$; $-(CR^1R^{15})_oR^{35}$; or $-(CHR^1)_nO(CHR^2)_mR^{35}$; or

R^4 and R^2 taken together can form

=O; $-(CHR^{15})_p-$; $-(CH_2)_nO(CH_2)_m-$; $-(CH_2)_nS(CH_2)_m-$; or $-(CH_2)_nNR^1(CH_2)_m-$; or

R^4 and R^5; R^5 and R^6; R^6 and R^7; R^7 and R^8; or R^6 and R^9 taken together can form:

$-(CHR^{15})_p-$; $-(CH_2)_nO(CH_2)_m-$; $-(CH_2)_nS(CH_2)_m-$; or $-(CH_2)_nNR^1(CH_2)_m-$; or

R^4 and R^5 are independently X;

R^9, R^{10}, R^{11} and R^{12} are independently

H; F; CF_3; lower alkyl; lower alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; $-(CHR^{15})_rOR^{17}$; $-(CHR^{15})_rSR^{17}$; $-(CHR^{15})_rNR^{17}R^{18}$; $-(CHR^{15})_rOCONR^{17}R^{18}$; $-(CHR^{15})_rNR^1CONR^{17}R^{18}$; $-(CHR^{15})_rNR^1COR^{17}$; $-(CHR^{15})_oCOOR^{17}$; $-(CHR^{15})_oCONR^{17}R^{18}$; $-(CHR^{15})_rPO(OR^1)_2$; $-(CHR^{15})_rSO_2R^{17}$; $-(CHR^{15})_rNR^1SO_2R^{17}$; $-(CHR^{15})_rSO_2NR^{17}R^{18}$; $-(CR^1R^{15})_oR^{35}$; or

$-(CHR^1)_rO(CHR^1)_oR^{35}$; or

R^{11} and R^{12} taken together can form

=O; or $=NR^1$;

R^{13} and R^{14} are independently

H; F; Cl; Br; CF_3; OCF_3; $OCHF_2$; CN; NO_2; lower alkyl; lower alkenyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; $-(CHR^{15})_oOR^{17}$; $-(CHR^{15})_oSR^{17}$; $-(CHR^{15})_oNR^{17}R^{18}$; $-(CHR^{15})_oOCONR^{17}R^{18}$; $-(CHR^{15})_oNR^1CONR^{17}R^{18}$; $-(CHR^{15})_oNR^1COR^{17}$; $-(CHR^{15})_oCOOR^{17}$; $-(CHR^{15})_oCONR^{17}R^{18}$; $-(CHR^{15})_oPO(OR^1)_2$; $-(CHR^{15})_oSO_2R^{17}$; $-(CHR^{15})_oNR^1SO_2R^{17}$; $-(CHR^{15})_oSO_2NR^{17}R^{18}$; $-(CR^1R^{15})_oR^{35}$; or $-(CHR^1)_rO(CHR^1)_oR^{35}$;

R^{15} is H; F; CF_3; lower alkyl; lower alkenyl; cycloalkyl; heterocycloalkyl; cycloalkyl-lower alkyl; heterocycloalkyl-lower alkyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; $-(CHR^1)_oOR^{17}$; $-(CHR^1)_oSR^{17}$; $-(CHR^1)_oNR^{17}R^{18}$; $-(CHR^1)_oNR^{20}C(=NR^{19})NR^{17}R^{18}$; $-(CHR^1)_oCOOR^{17}$; $-(CHR^1)_oCONR^{17}R^{18}$; $-(CHR^1)_oSO_2R^{17}$; or $-(CHR^1)_oSO_2NR^{17}R^{18}$;

R^{16} is CF_3; lower alkyl; lower alkenyl; cycloalkyl; heterocycloalkyl; cycloalkyl-lower alkyl; heterocycloalkyl-lower alkyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; cycloalkyl-aryl; heterocycloalkyl-aryl; cycloalkyl-heteroaryl; heterocycloalkyl-heteroaryl; aryl-cycloalkyl; aryl-heterocycloalkyl; heteroaryl-cycloalkyl; heteroaryl-heterocycloalkyl; $-(CHR^1)_sOR^{17}$; $-(CHR^1)_sSR^{17}$; $-(CHR^1)_sNR^{17}R^{18}$; $-(CHR^1)_oCOR^{17}$; $-(CHR^1)_oCOOR^{17}$; $-(CHR^1)_oCONR^{17}R^{18}$; or $-(CHR^1)_oSO_2R^{17}$;


R^{17}, R^{18}, R^{19} and R^{20} are independently

H; lower alkyl; lower alkenyl; lower alkoxy; cycloalkyl; heterocycloalkyl; cycloalkyl-lower alkyl; heterocycloalkyl-lower alkyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; cycloalkyl-aryl; heterocycloalkyl-aryl; cycloalkyl-heteroaryl; heterocycloalkyl-heteroaryl; aryl-cycloalkyl; aryl-heterocycloalkyl; heteroaryl-cycloalkyl; or heteroaryl-heterocycloalkyl; or

the structural elements $-NR^{17}R^{18}$ and $-NR^{19}R^{20}$ can independently form:

~~heterocycloalkyl; aryl-heterocycloalkyl; or heteroaryl-heterocycloalkyl;~~

or a group of one of the formulae



Z, Z' and Z'' are independently

-CR^{39}; or N;

R^{21}, R^{22}, R^{23} and R^{24} are independently

H; F; CF_3; lower alkyl; lower alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; -$(CHR^1)_oOR^{17}$; -$(CHR^1)_oSR^{17}$; -$(CHR^1)_oNR^2R^{17}$; -$(CHR^1)_oOCONR^2R^{17}$; -$(CHR^1)_oNR^2CONR^3R^{17}$; -$(CHR^1)_oNR^2COR^{17}$; -$(CHR^1)_oCOOR^{17}$; -$(CHR^1)_oCONR^2R^{17}$; -$(CHR^1)_oPO(OR^2)_2$; -$(CHR^1)_oSO_2R^{17}$; -$(CHR^1)_oNR^2SO_2R^{17}$; -$(CHR^1)_oSO_2NR^2R^{17}$; -$(CR^1R^2)_oR^{38}$; or -$(CHR^1)_nO(CHR^2)_mR^{38}$;

R^{25} and R^{26} are independently

H; F; CF_3; lower alkyl; lower alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; -$(CHR^1)_rOR^{17}$; -$(CHR^1)_rSR^{17}$; -$(CHR^1)_rNR^2R^{17}$; -$(CHR^1)_rOCONR^2R^{17}$; -$(CHR^1)_rNR^2CONR^3R^{17}$;-$(CHR^1)_rNR^2COR^{17}$; -$(CHR^1)_oCOOR^{17}$; -$(CHR^1)_oCONR^2R^{17}$; -$(CHR^1)_rPO(OR^2)_2$; -$(CHR^1)_rSO_2R^{17}$; -$(CHR^1)_rNR^2SO_2R^{17}$; -$(CHR^1)_rSO_2NR^2R^{17}$; -$(CR^1R^2)_oR^{38}$; or -$(CHR^1)_rO(CHR^2)_oR^{38}$;

~~R^{27} is H; F; Cl; Br; CF_3; OCF_3; $OCHF_2$; CN; NO_2; lower alkyl; lower alkenyl; aryl;~~
heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; $-(CHR^1)_oOR^{17}$;
$-(CHR^1)_oSR^{17}$; $-(CHR^1)_oNR^2R^{17}$; $-(CHR^1)_oOCONR^2R^{17}$; $-(CHR^1)_oNR^2CONR^2R^{17}$;
$-(CHR^1)_oNR^2COR^{17}$; $-(CHR^1)_oCOOR^{17}$; $-(CHR^1)_oCONR^2R^{17}$; $-(CHR^1)_oPO(OR^2)_2$;
$-(CHR^1)_oSO_2R^{17}$; $-(CHR^1)_oNR^2SO_2R^{17}$; $-(CHR^1)_oSO_2NR^2R^{17}$; $-(CR^1R^2)_oR^{38}$; or
$-(CHR^1)_rO(CHR^2)_oR^{38}$;

R^{29} is H; alkyl; alkenyl; cycloalkyl-lower alkyl; heterocycloalkyl-lower alkyl;
$-(CHR^4)_oOR^{17}$; $-(CHR^4)_oSR^{17}$; or $-(CHR^4)_rNR^{17}R^{18}$;

R^{30} is $-(CR^1R^4)_nR^{35}$; $-(CH_2)_nO(CH_2)_mR^{35}$; $-(CH_2)_nS(CH_2)_mR^{35}$; or $-(CH_2)_nNR^1(CH_2)_mR^{35}$;


R^{31} is alkyl; alkenyl; $-(CR^1R^{15})_qNR^{17}R^{18}$; $-(CR^1R^{15})_qNR^2R^{16}$; $-(CR^1R^{15})_qNR^{17}R^{32}$;
$-(CR^1R^{15})_qNR^{17}COR^{18}$; $-(CH_2)_qC(=NR^{15})NR^{17}R^{18}$; $-(CH_2)_qC(=NOR^{19})NR^{17}R^{18}$;
$-(CH_2)_qC(=NNR^{17}R^{18})NR^{19}R^{20}$; $-(CR^1R^{15})_qNR^{20}C(=NR^{19})NR^{17}R^{18}$;
$-(CR^1R^{15})_qN=C(NR^{17}R^{18})NR^{19}R^{20}$; $-(CR^1R^{15})_qOR^{17}$; $-(CR^1R^{15})_qOR^{32}$;
$-(CR^1R^{15})_qSR^{17}$; $-(CR^1R^{15})_qSO_2R^{17}$; $-(CR^1R^{15})_qNR^{17}SO_2R^{18}$; $-(CR^1R^{15})_qSO_2NR^2R^{16}$;
$-(CR^1R^{15})_qSO_2NR^{17}R^{18}$; $-(CR^1R^{15})_qNR^{19}SO_2NR^{17}R^{18}$; $-(CR^1R^{15})_qPO(OR^2)_2$;
$-(CH_2)_nO(CH_2)_mNR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mC(=NR^{19})NR^{17}R^{18}$;
$-(CH_2)_nO(CH_2)_mC(=NOR^{19})NR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mC(=NNR^{17}R^{18})NR^{19}R^{20}$;
$-(CH_2)_nO(CH_2)_mNR^{20}C(=NR^{19})NR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mN=C(NR^{17}R^{18})NR^{19}R^{20}$;
$-(CH_2)_nS(CH_2)_mNR^{17}R^{18}$; $-(CH_2)_nS(CH_2)_mC(=NR^{19})NR^{17}R^{18}$;
$-(CH_2)_nS(CH_2)_mC(=NOR^{19})NR^{17}R^{18}$; $-(CH_2)_nS(CH_2)_mC(=NNR^{17}R^{18})NR^{19}R^{20}$;
$-(CH_2)_nS(CH_2)_mNR^{20}C(=NR^{19})NR^{17}R^{18}$; $-(CH_2)_nS(CH_2)_mN=C(NR^{17}R^{18})NR^{19}R^{20}$;
$-(CR^1R^{15})_qCOOR^{17}$; $-(CR^1R^{15})_qCONR^{17}R^{18}$; or $-(CR^1R^{15})_qCOR^{33}$;

R^{32} is $-COR^{29}$; $-COR^{30}$; $-CO(CR^1R^{15})_oR^{17}$; $-CO(CR^1R^{15})_oOR^{17}$; $-CO(CR^1R^{15})_oNR^{17}R^{18}$;
$-CO(CR^1R^{15})_oNR^2R^{16}$; $-CO(CR^1R^{29})NR^{17}R^{18}$; $-CO(CR^1R^{30})NR^{17}R^{18}$;
$-CO(CR^1R^{34})NR^{17}R^{18}$; $-CO(CHR^1)_oCONR^{17}R^{18}$; $-CO(CHR^1)_oCONR^{17}SO_2R^{18}$;
$-CO(CR^1R^{15})_oNR^{17}SO_2R^{18}$; $-CONR^1(CHR^{17})_nNR^2(CHR^{15})_mR^{16}$;
$-CO(CHR^{17})_nO(CHR^{15})_mR^{16}$; $-CONR^1(CHR^{17})_nO(CHR^{15})_mR^{16}$; $-SO_2R^{29}$;
$-SO_2R^{30}$; $-SO_2(CR^1R^{15})_oR^{17}$; or $-SO_2(CR^1R^{15})_oNR^{17}R^{18}$;


R^{33} is $-NR^1C(R^2)(R^{29})COOR^{17}$; $-NR^1C(R^2)(R^{29})CONR^{17}R^{18}$; $-NR^1C(R^2)(R^{30})COOR^{17}$;
~~$-NR^1C(R^2)(R^{30})CONR^{17}R^{18}$; $-NR^1C(R^2)(R^{34})COOR^{17}$; or $-NR^1C(R^2)(R^{34})CONR^{17}R^{18}$;~~

R^{34} is $-(CR^1R^{15})_qNR^{17}R^{18}$; $-(CH_2)_qC(=NR^{19})NR^{17}R^{18}$; $-(CH_2)_qC(=NOR^{19})NR^{17}R^{18}$; $-(CH_2)_qC(=NNR^{17}R^{18})NR^{19}R^{20}$; $-(CR^1R^{15})_qNR^2C(=NR^{19})NR^{17}R^{18}$; $-(CR^1R^{15})_qN=C(NR^{17}R^{18})NR^{19}R^{20}$; $-(CR^1R^{15})_qOR^{17}$; $-(CR^1R^{15})_qSR^{17}$; $-(CR^1R^{15})_qSO_2R^{17}$; $-(CR^1R^{15})_qNR^{17}SO_2R^{18}$; $-(CR^1R^{15})_qSO_2NR^1R^{16}$; $-(CR^1R^{15})_qSO_2NR^{17}R^{18}$; $-(CR^1R^{15})_qNR^2SO_2NR^{17}R^{18}$; $-(CR^1R^{15})_qPO(OR^1)_2$; $-(CH_2)_nO(CH_2)_mNR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mC(=NR^{19})NR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mC(=NOR^{19})NR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mC(=NNR^{17}R^{18})NR^{19}R^{20}$; $-(CH_2)_nO(CH_2)_mNR^{20}C(=NR^{19})NR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mN=C(NR^{17}R^{18})NR^{19}R^{20}$; $-(CH_2)_nS(CH_2)_mNR^{17}R^{18}$; $-(CH_2)_nS(CH_2)_mC(=NR^{19})NR^{17}R^{18}$; $-(CH_2)_nS(CH_2)_mC(=NOR^{19})NR^{17}R^{18}$; $-(CH_2)_nS(CH_2)_mC(=NNR^{17}R^{18})NR^{19}R^{20}$; $-(CH_2)_nS(CH_2)_mNR^{20}C(=NR^{19})NR^{17}R^{18}$; $-(CH_2)_nS(CH_2)_mN=C(NR^{17}R^{18})NR^{19}R^{20}$; $-(CR^1R^{15})_qCOOR^{17}$; or $-(CR^1R^{15})_qCONR^{17}R^{18}$;


R^{35} is an aryl group of one of the formulae



AR1




AR2




AR3


or a heteroaryl group of one of the formulae




H1




H2




H3




H4




H5




H6




H7




H8




H9




H10




H11




H12




H13




H14



H15



H16
H17
H18
H19
H20
H21
H22
H23
H24
H25
H26
H27
H28
H29
H30
H31
H32
H33
H34
H35
H36
H37
H38
H39
H40
H41
H42
H43
H44



R^{36} and R^{37} are independently

H; F; Cl; Br; CF_3; OCF_3; $OCHF_2$; CN; NO_2; lower alkyl; lower alkenyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; $-(CH_2)_oR^{38}$; $-(CH_2)_oOR^{17}$; $-O(CH_2)_oR^{38}$; $-(CH_2)_oSR^{17}$; $-(CH_2)_oNR^{17}R^{18}$; $-(CH_2)_oOCONR^{17}R^{18}$; $-(CH_2)_oNR^1CONR^{17}R^{18}$; $-(CH_2)_oNR^1COR^{17}$; $-(CH_2)_oCOOR^{17}$; $-(CH_2)_oCONR^{17}R^{18}$; $-(CH_2)_oPO(OR^1)_2$; $-(CH_2)_oSO_2R^{16}$; or $-(CH_2)_oCOR^{17}$;

R^{38} is an aryl group of the formula



R^{39}, R^{40} and R^{41} are independently

H; F; Cl; Br; OH; NH_2; NO_2; CN; CF_3; $OCHF_2$; OCF_3; $-NR^1R^{17}$; $-(CH_2)_oCOOR^{17}$; $-(CH_2)_oCONR^1R^{17}$; lower alkyl; lower alkoxy; or lower alkenyl;

R^{42} is H; lower alkyl; or aryl-lower alkyl;

n and m are independently an integer of 0-5 with the proviso that $n+m \leq 6$;

o is 0-4; p is 2-6; q is 1-6; r is 1-3; s is 0-4

and pharmaceutically acceptable salts thereof.

2. ~~Compounds according to claim 1 wherein~~

R^{16} is CF_3; lower alkyl; lower alkenyl; cycloalkyl; heterocycloalkyl; cycloalkyl-lower alkyl; heterocycloalkyl-lower alkyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; $-(CHR^1)_sOR^{17}$; $-(CHR^1)_sSR^{17}$; $-(CHR^1)_sNR^{17}R^{18}$; $-(CHR^1)_oCOR^{17}$; $-(CHR^1)_oCOOR^{17}$; $-(CHR^1)_oCONR^{17}R^{18}$; or $-(CHR^1)_oSO_2R^{17}$;

R^{17}, R^{18}, R^{19} and R^{20} are independently H; lower alkyl; lower alkenyl; lower alkoxy; cycloalkyl; heterocycloalkyl; cycloalkyl-lower alkyl; heterocycloalkyl-lower alkyl; aryl; heteroaryl; aryl-lower alkyl; or heteroaryl-lower alkyl; or

the structural elements $-NR^{17}R^{18}$ and $-NR^{19}R^{20}$ can independently form: heterocycloalkyl; aryl-heterocycloalkyl; or heteroaryl-heterocycloalkyl; or a group of one of the above formulae C1 to C8;

R^{31} is alkyl; alkenyl; $-(CR^1R^{15})_qNR^{17}R^{18}$; $-(CR^1R^{15})_qNR^2R^{16}$; $-(CR^1R^{15})_qNR^{17}COR^{18}$; $-(CH_2)_qC(=NR^{15})NR^{17}R^{18}$; $-(CR^1R^{15})_qNR^{20}C(=NR^{19})NR^{17}R^{18}$; $-(CR^1R^{15})_qOR^{17}$; $-(CR^1R^{15})_qSR^{17}$; $-(CR^1R^{15})_qSO_2R^{17}$; $-(CR^1R^{15})_qNR^{17}SO_2R^{18}$; $-(CR^1R^{15})_qSO_2NR^2R^{16}$; $-(CR^1R^{15})_qSO_2NR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mNR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mC(=NR^{19})NR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mNR^{20}C(=NR^{19})NR^{17}R^{18}$; $-(CH_2)_nS(CH_2)_mNR^{17}R^{18}$; $-(CH_2)_nS(CH_2)_mNR^{20}C(=NR^{19})NR^{17}R^{18}$; $-(CR^1R^{15})_qCONR^{17}R^{18}$; or $-(CR^1R^{15})_qCOR^{33}$;

s is 2-4

and pharmaceutically acceptable salts thereof.

3. Compounds according to claim 1 wherein

T^1 is ^{D}Pro; ^{D}Pip; ^{D}Tic; ^{D}Tiq; ^{D}Oic; ^{D}Azt; ^{D}Pro((3*R*)OH); ^{D}Pro((3*S*)OH); ^{D}Pro((3*R*)NH_2); ^{D}Pro((3*S*)NH_2); ^{D}Pro((4*R*)OH); ^{D}Pro((4*S*)OH); ^{D}Pro((4*R*)NH_2); ^{D}Pro((4*S*)NH_2); ^{D}Pro((4*S*)NHBz); or ^{D}Mor;

T^2 is Thr; *allo*Thr; Ser; hSer; Pro((3*R*)OH); Pro((3*S*)OH); Hyp(Bn); (4*S*)-Hyp(Bn); Pro((3*R*)NH_2); Pro((3*S*)NH_2); Pro((4*R*)NH_2); Pro((4*S*)NH_2); Pro((4*S*)F); Pro((4*S*)NHBz); or Mor; or

~~when T^1 is ^{D}Pro((3*R*)OH); ^{D}Pro((3*S*)OH); ^{D}Pro((3*R*)NH_2); ^{D}Pro((3*S*)NH_2); ^{D}Pro((4*R*)NH_2);~~

^{D}Pro((4*S*)NH_2); ^{D}Pro((4*S*)NHBz); or ^{D}Mor

then T^2 can in addition be

Pro; Pip; Tic; Tiq; Oic; or Azt;

P^1, P^3 and P^4 are independently

Ala; Arg; Asn; Asp; Cit; Cys; Glu; Gln; Gly; His; Ile; Leu; Lys; Met; Orn; Phe; Pro; Ser; Thr; Trp; Tyr; Val; Abu; Agb; Agp; Ala(*t*Bu); Ala(*c*Pr); Ala(2Furyl); Ala(3Furyl); Ala(Ppz); Ala(1Pyraz); Ala(2Quin); Ala(3Quin); Ala(4Quin); Ala(Tet); Azt; Bbta; Bip; Cha; Chg; Dab; Dab(Ac); Dab(*c*Pr); Dab(*i*Pr); Dab($4Me_2NPhSO_2$); Dab(MeOEtNCO); Dab(MePpzCO); Dab($MeSO_2$); Dab(morphCO); Dab(1Nal); Dab(2Nal); Dap; Dap($CONH_2$); Dap(MeOEt); Dap($(MeOEt)_2$); Deg; Gly(*t*Bu); hArg; hCha; hCys; hHis; hLys; hPhe; hSer; hSer(Me); hTrp; hTyr; His(Me); His(Bn); Hyp(Bn); (4*S*)-Hyp(Bn); Hyp(4BrBn); Hyp(3CNBn); Hyp(4CNBn); Hyp(CONHPh); Hyp(Ph); Lys(Ac); Lys(Bz); Lys(*c*Pr); Lys(*i*Pr); Lys(Me); Lys(Nic); Lys((5*R*)OH); Lys(4Oxa); Met(O_2); 1Nal; 2Nal; Nle; Nle(6OBn); OctG; Oic; Orn(*c*Pr); Orn(*i*Pr); 2Pal; 3Pal; 4Pal; Phe(2Cl); Phe(3Cl); Phe(4Cl); Phe(3,4Cl_2); Phe(2F); Phe(3F); Phe(4F); Phe(4CN); Phe(4CF_3); Phe(4COOMe); Phg; Pip; Pro((4*R*)Bn); Pro((4*S*)F); Pro((4*S*)*c*Hex); Pro(5,5Me_2); Ser(Bn); Ser(Me); Thi; *allo*Thr; Thr(Bn); Thz; Thz(5,5Me_2); Tic; Tic(7OH); Trp(7Aza); Trp(5Br); Trp(6Br); Trp(6CF_3); Trp(5Cl); Trp(6Cl); Trp(5,6Cl); Trp(5OH); Tyr(Bn); Tyr(Me); Tyr(4MeOCOBn); Tyr(Ph); Tyr(4OHPh); Tza; Gln(Alk1); Gln(Alk2); Gln(Alk3); Gln(Alk4); Gln(Alk5); Gln(Alk6); Gln(Alk7); Gln(Alk8); Gln(Alk9); Gln(Alk10); Gln(Alk11); Gln(Alk12); Gln(Alk13); Gln(Alk14); Gln(Alk15); Gln(Alk16); Gln(Alk17); Gln(Alk18); Gln(Alk19); Gln(Alk20); Gln(Alk21); Gln(Alk22); Gln(Alk23); Gln(Alk24); Gln(Alk25); Gln(Alk26); Gln(Alk27); Gln(Alk28); Gln(Alk29); Gln(Alk30); Gln(Alk31); Gln(Alk32); Gln(Alk33); Gln(Alk34); Glu(cN1); Glu(cN2); Glu(cN3); Glu(cN4); Glu(cN5); Glu(cN6); Glu(cN7); Glu(cN8); Glu(cN9); Glu(cN10); Glu(cN11); Glu(cN12); Glu(cN13); Glu(cN14); Glu(cN15); Glu(cN16); Glu(cN17); Lys(Ar1); ~~Lys(Ar2); Lys(Ar3); Lys(Ar4); Lys(Ar5); Lys(Ar6); Lys(Ar7); Lys(Ar8); Lys(Ar9);~~

~~Lys(Ar10); Lys(Ar11); Lys(Ar12); Orn(Ar1); Orn(Ar2); Orn(Ar3); Orn(Ar4);~~ Orn(Ar5); Orn(Ar6); Orn(Ar7); Orn(Ar8); Orn(Ar9); Orn(Ar10); Orn(Ar11); Orn(Ar12); Dab(Ar1); Dab(Ar2); Dab(Ar3); Dab(Ar4); Dab(Ar5); Dab(Ar6); Dab(Ar7); Dab(Ar8); Dab(Ar9); Dab(Ar10); Dab(Ar11); Dab(Ar12); Dab(S1); Dab(S2); Dab(S3); Dab(S4); Dab(S5); Dab(S6); Dab(S7); Dab(S8); Dab(S9); Dab(S10); Dab(S11); Dab(S12); Dab(S13); Dab(S14); Dab(S15); Dab(S16); Dab(S17); Dab(S18); Dab(A1); Dab(A2); Dab(A3); Dab(A4); Dab(A5); Dab(A6); Dab(A7); Dab(A8); Dab(A9); Dab(A10); Dab(A11); Dab(A12); Dab(A13); Dab(A14); Dab(A15); Dab(A16); Dab(A17); Dab(A18); Dab(A19); Dab(A20); Dab(A21); Dab(A22); Dab(A23); Dab(A24); Dab(A25); Dab(A26); Dab(A27); Dab(A28); Dab(A29); Dab(A30); Dab(A31); Dab(A32); Dab(A33); Dab(A34); Dab(A35); Dab(A36); Dab(A37); Dab(A38); Dab(A39); Dab(A40); Dab(A41); Dab(A42); Dab(A43); Dab(A44); Dab(A45); Dab(A46); Dab(A47); Dab(A48); Dab(A49); Dab(A50); Dab(A51); Dab(A52); Dab(A53); Dab(A54); Dab(A55); Orn(A1); Orn(A2); Orn(A3); Orn(A4); Orn(A5); Orn(A6); Orn(A7); Orn(A8); Orn(A9); Orn(A10); Orn(A11); Orn(A12); Orn(A13); Orn(A14); Orn(A15); Orn(A16); Orn(A17); Orn(A18); Orn(A19); Orn(A20); Orn(A21); Orn(A22); Orn(A23); Orn(A24); Orn(A25); Orn(A26); Orn(A27); Orn(A28); Orn(A29); Orn(A30); Orn(A31); Orn(A32); Orn(A33); Orn(A34); Orn(A35); Orn(A36); Orn(A37); Orn(A38); Orn(A39); Orn(A40); Orn(A41); Orn(A42); Orn(A43); Orn(A44); Orn(A45); Orn(A46); Orn(A47); Orn(A48); Orn(A49); Orn(A50); Orn(A51); Orn(A52); Orn(A53); Orn(A54); Orn(A55); Orn(A56); Asn(Alk1); Asn(Alk2); Asn(Alk3); Asn(Alk4); Asn(Alk5); Asn(Alk6); Asn(Alk7); Asn(Alk8); Asn(Alk9); Asn(Alk10); Asn(Alk11); Asn(Alk12); Asn(Alk13); Asn(Alk14); Asn(Alk15); Asn(Alk16); Asn(Alk17); Asn(Alk18); Asn(Alk19); Asn(Alk20); Asn(Alk21); Asn(Alk22); Asn(Alk23); Asn(Alk24); Asn(Alk25); Asn(Alk26); Asn(Alk27); Asn(Alk28); Asn(Alk29); Asn(Alk30); Asn(Alk31); Asn(Alk32); Asn(Alk33); Asn(Alk34); Asp(cN1); Asp(cN2); Asp(cN3); Asp(cN4); Asp(cN5); Asp(cN6); Asp(cN7); Asp(cN8); Asp(cN9); Asp(cN10); Asp(cN11); Asp(cN12); ~~Asp(cN13); Asp(cN14); Asp(cN15); Asp(cN16); Asp(cN17); Dap(Ar1); Dap(Ar2);~~

Dap(Ar3); Dap(Ar4); Dap(Ar5); Dap(Ar6); Dap(Ar7); Dap(Ar8); Dap(Ar9); Dap(Ar10); Dap(Ar11); Dap(Ar12); Dap(S1); Dap(S2); Dap(S3); Dap(S4); Dap(S5); Dap(S6); Dap(S7); Dap(S8); Dap(S9); Dap(S10); Dap(S11); Dap(S12); Dap(S13); Dap(S14); Dap(S15); Dap(S16); Dap(S17); Dap(S18); Dap(A1); Dap(A2); Dap(A3); Dap(A4); Dap(A5); Dap(A6); Dap(A7); Dap(A8); Dap(A9); Dap(A10); Dap(A11); Dap(A12); Dap(A13); Dap(A14); Dap(A15); Dap(A16); Dap(A17); Dap(A18); Dap(A19); Dap(A20); Dap(A21); Dap(A22); Dap(A23); Dap(A24); Dap(A25); Dap(A26); Dap(A27); Dap(A28); Dap(A29); Dap(A30); Dap(A31); Dap(A32); Dap(A33); Dap(A34); Dap(A35); Dap(A36); Dap(A37); Dap(A38); Dap(A39); Dap(A40); Dap(A41); Dap(A42); Dap(A43); Dap(A44); Dap(A45); Dap(A46); Dap(A47); Dap(A48); Dap(A49); Dap(A50); Dap(A51); Dap(A52); Dap(A53); Dap(A54); or Dap(A55);

P^2 is ^{D}Arg; ^{D}hArg; ^{D}Agb; ^{D}Lys; ^{D}Orn; ^{D}Cit; ^{D}Thr; ^{D}Dab; ^{D}Dab; ^{D}Phe; ^{D}Phe(4CF_3); ^{D}Trp; ^{D}His; ^{D}Tyr; ^{D}2Pal; ^{D}3Pal; ^{D}4Pal; ^{D}Lys(Ar1); ^{D}Lys(Ar2); ^{D}Lys(Ar3); ^{D}Lys(Ar4); ^{D}Lys(Ar5); ^{D}Lys(Ar6); ^{D}Lys(Ar7); ^{D}Lys(Ar8); ^{D}Lys(Ar9); ^{D}Lys(Ar10); ^{D}Lys(Ar11); ^{D}Lys(Ar12); ^{D}Orn(A41); ^{D}Orn(A56); ^{D}Orn(Ar1); ^{D}Orn(Ar2); ^{D}Orn(Ar3); ^{D}Orn(Ar4); ^{D}Orn(Ar5); ^{D}Orn(Ar6); ^{D}Orn(Ar7); ^{D}Orn(Ar8); ^{D}Orn(Ar9); ^{D}Orn(Ar10); ^{D}Orn(Ar11); ^{D}Orn(Ar12); ^{D}Dab(Ar1); ^{D}Dab(Ar2); ^{D}Dab(Ar3); ^{D}Dab(Ar4); ^{D}Dab(Ar5); ^{D}Dab(Ar6); ^{D}Dab(Ar7); ^{D}Dab(Ar8); ^{D}Dab(Ar9); ^{D}Dab(Ar10); ^{D}Dab(Ar11); ^{D}Dab(Ar12); ^{D}Dap(Ar1); ^{D}Dap(Ar2); ^{D}Dap(Ar3); ^{D}Dap(Ar4); ^{D}Dap(Ar5); ^{D}Dap(Ar6); ^{D}Dap(Ar7); ^{D}Dap(Ar8); ^{D}Dap(Ar9); ^{D}Dap(Ar10); ^{D}Dap(Ar11); or ^{D}Dap(Ar12);

and pharmaceutically acceptable salts thereof.

4. Compounds according to claim 1 wherein

T^1 is ^{D}Pro; ^{D}Pip; ^{D}Tic; ^{D}Tiq; ^{D}Oic; ^{D}Azt; ^{D}Pro((3*R*)OH); ^{D}Pro((3*S*)OH); ^{D}Pro((3*R*)NH_2); ^{D}Pro((3*S*)NH_2); ^{D}Pro((4*R*)OH); ^{D}Pro((4*S*)OH); ^{D}Pro((4*R*)NH_2); ^{D}Pro((4*S*)NH_2); ^{D}Pro((4*S*)NHBz); or ^{D}Mor;

T^2 is Thr; *allo*Thr; Ser; hSer; Pro((3*R*)OH); Pro((3*S*)OH); Hyp(Bn); (4*S*)-Hyp(Bn); Pro((3*R*)NH_2); Pro((3*S*)NH_2); Pro((4*R*)NH_2); Pro((4*S*)NH_2); Pro((4*S*)F); Pro((4*S*)NHBz); or Mor; or

when T^1 is ^{D}Pro((3*R*)OH); ^{D}Pro((3*S*)OH); ^{D}Pro((3*R*)NH_2); ^{D}Pro((3*S*)NH_2); ^{D}Pro((4*R*)NH_2); ^{D}Pro((4*S*)NH_2); ^{D}Pro((4*S*)NHBz); or ^{D}Mor

then T^2 can in addition be

Pro; Pip; Tic; Tiq; Oic; or Azt;

P^1 is Ile; Nle; Leu; Val; Chg; Cha; Abu; Ala; Ala(*c*Pr); Ala(1Pyraz); Ala(Tet); Trp; 1Nal; 2Nal; Phe; Tyr; 2Pal; 3Pal; 4Pal; Thr; His; Arg; hArg; Agb; Pip; Orn(Ar2); or Orn(A56);

P^2 is ^{D}Arg; ^{D}hArg; ^{D}Agb; ^{D}Lys; ^{D}Orn; ^{D}Cit; ^{D}Thr; ^{D}Dab; ^{D}Dap; ^{D}Phe; ^{D}Trp; ^{D}His; ^{D}Tyr; ^{D}2Pal; ^{D}3Pal; or ^{D}4Pal;

P^3 is Arg; hArg; Agb; Agp; Lys; Orn; Orn(A41); Orn(A56); Orn(Ar2); Orn(Ar4); Orn(Ar7); Cit; Thr; Dab; Dap; Phe; Trp; His; Tyr; or Ile

P^4 is Trp; His; Phe; Phe(4CF_3); 1Nal; 2Nal; Tyr; Leu; Ile; Arg; hArg; Lys; Dab; Dap; Orn; Orn(A56); or Orn(Ar7);

and pharmaceutically acceptable salts thereof.

5. Compounds according to claim 1 wherein

T^1 is ^{D}Pro; ^{D}Pip; ^{D}Tic; ^{D}Pro((4*S*)OH); ^{D}Pro((4*R*)NH_2); or ^{D}Pro((4*S*)NH_2);

T^2 is Thr; *allo*Thr; Ser; hSer; Pro((3*S*)OH); (4*S*)-Hyp(Bn); Pro((4*R*)NH_2); Pro((4*S*)NH_2); Pro((4*S*)F); Pro((4*S*)NHBz); or Mor;

P^1 is Ile; Nle; Leu; Val; Chg; Cha; Abu; Ala; Trp; 1Nal; Tyr; 3Pal; Thr; His; Arg; hArg; Agb; Pip; Ala(1Pyraz); Ala(Tet); Orn(Ar2); or Orn(A56);

P^2 is ^{D}Arg; ^{D}Lys; ^{D}Orn; ^{D}Cit; ^{D}Thr; ^{D}Dab; ^{D}Phe; ^{D}Trp; ^{D}His; or ^{D}3Pal;

P^3 is Arg; hArg; Agb; Agp; Lys; Orn; Orn(A41); Orn(A56); Orn(Ar2); Orn(Ar4); Orn(Ar7); Dab; Trp; or His;

P^4 is Trp; His; Phe; Phe($4CF_3$); 1Nal; 2Nal; Tyr; Ile; Arg; hArg; Lys; Dab; Orn; Orn(A56); or Orn(Ar7);

and pharmaceutically acceptable salts thereof.

6. Compounds according claim 1 selected from

cyclo(-Ile-^{D}Arg-Arg-Ile-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Arg-Tyr-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Lys-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Dab-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Dab-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Arg-Phe-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Thr-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pro-hSer-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pro-*allo*Thr-);

cyclo(-1Nal-^{D}Arg-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Lys-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}His-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Cit-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pip-Thr-);

cyclo(-Ile-^{D}Arg-Arg-2Nal-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Arg-1Nal-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Trp-Arg-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Thr-^{D}Arg-Trp-Arg-^{D}Pro-Thr-);

cyclo(-Trp-^{D}Arg-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pro-Pro((3*S*)OH)-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pro-Ser-);

cyclo(-Ile-^{D}Arg-Agp-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Agb-Trp-^{D}Pro-Thr-);

cyclo(-Trp-^{D}Phe-Trp-Arg-^{D}Pro((4*S*)NH_2)-Tic-);

cyclo(-Trp-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Ala-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Tyr-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Trp-^{D}Phe-Trp-Orn-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Trp-^{D}Phe-Trp-Dab-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Trp-^{D}Phe-Trp-Lys-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Trp-^{D}Phe-Trp-His-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Arg-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Pip-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-hArg-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Agb-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-3Pal-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Trp-^{D}3Pal-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Arg-^{D}Phe-Trp-hArg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Arg-^{D}Phe-Trp-Arg-^{D}Pro((4*S*)NH_2)-Tic-);

cyclo(-Trp-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Oic-);

cyclo(-Arg-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Oic-);

cyclo(-Trp-^{D}Phe-Trp-Arg-^{D}Pro-Pro((4*S*)F)-);

cyclo(-Trp-^{D}Phe-Trp-Arg-^{D}Pro-Pro((4*S*)NH_2)-);

cyclo(-Trp-^{D}Phe-Trp-Arg-^{D}Pro-Pro((4*R*)NH_2)-);

cyclo(-Trp-^{D}Phe-Trp-Arg-^{D}Pro-Mor-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pro-Mor-);

cyclo(-Arg-^{D}Phe-Trp-Arg-^{D}Pro-(4*S*)-Hyp(Bn)-);

cyclo(-Trp-^{D}Phe-Trp-Arg-^{D}Pro((4*S*)OH)-(4*S*)-Hyp(Bn)-);

cyclo(-Trp-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-(4*S*)-Hyp(Bn)-);

cyclo(-His-^{D}Trp-His-Trp-^{D}Pro- Pro((4*S*)NHBz)-);

cyclo(-1Nal-^{D}Arg-Arg-Trp-^{D}Pro-Pro((3*S*)OH)-);

cyclo(-Ile-^{D}Arg-Arg-2Nal-^{D}Pro-Pro((3*S*)OH)-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pip-Pro((3*S*)OH)-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pro((4*S*)OH)-Thr-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pro((4*R*)NH_2)-Thr-);

cyclo(-Val-^{D}Arg-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Abu-^{D}Arg-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Chg-^{D}Arg-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Leu-^{D}Arg-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Nle-^{D}Arg-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Cha-^{D}Arg-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Orn-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Orn(A41)-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Orn-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-hArg-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Tic-Thr-);

cyclo(-Ile-^{D}Arg-Orn(Ar2)-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Orn(Ar7)-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Orn(Ar4)-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Orn(A56)-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Arg-Phe(4CF_3)-^{D}Pro-Thr-);

cyclo(-Trp-^{D}Phe-Trp-Orn(A56)-^{D}Pip-Pro((3*S*)OH)-);

cyclo(-Ala(1Pyraz)-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Ala(Tet)-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Orn(Ar2)-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Orn(A56)-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Trp-^{D}Phe-Trp-Orn(Ar7)-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Trp-^{D}Phe-Trp-Orn(A56)-^{D}Pro((4*R*)NH_2)-Tiq-);

cyclo(-Trp-^{D}Phe-Trp-Orn(A56)-^{D}Pro((4*R*)NH_2)-Tic-);

and pharmaceutically acceptable salts thereof.

7. Compounds according claim 6 selected from

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pip-Thr-);

cyclo(-Ile-^{D}Arg-Arg-2Nal-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pro-Ser-);

cyclo(-Trp-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Trp-^{D}Phe-Trp-Dab-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-3Pal-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Trp-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Oic-);

cyclo(-Trp-^{D}Phe-Trp-Arg-^{D}Pro((4*S*)OH)-(4*S*)-Hyp(Bn)-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pip-Pro((3*S*)OH)-);

cyclo(-Chg-^{D}Arg-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-hArg-Trp-^{D}Pro-Thr-);

and pharmaceutically acceptable salts thereof.

8. Compounds according claim 6 selected from

cyclo(-Ile-^{D}Arg-Orn(Ar2)-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Orn(Ar7)-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Orn(Ar4)-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Orn(A56)-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Arg-Phe(4CF_3)-^{D}Pro-Thr-);

cyclo(-Trp-^{D}Phe-Trp-Orn(A56)-^{D}Pip-Pro((3*S*)OH)-);

cyclo(-Ala(1Pyraz)-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Ala(Tet)-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Orn(Ar2)-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Orn(Ar56)-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Trp-^{D}Phe-Trp-Orn(Ar7)-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Trp-^{D}Phe-Trp-Orn(A56)-^{D}Pro((4*R*)NH_2)-Tiq-);

cyclo(-Trp-^{D}Phe-Trp-Orn(A56)-^{D}Pro((4*R*)NH_2)-Tic-);

and pharmaceutically acceptable salts thereof.

9. Epimers and diastereomers of the compounds of formula **(I)** as defined in claim 1 based on one or more chiral center not explicitly specified in formula **(I)**.

10. Compounds according to any one of claims 1 to 9 for use as therapeutically active substances, especially for use as therapeutically active substances against diseases or conditions mediated or sustained through the activity of CXCR7.

11. Compounds according any one of claims 1 to 9 having modulating activity against the CXCR7 receptor, especially interfering selectively with the natural activity of the CXCR7 receptor and its natural ligands CXCL11 and/or CXCL12.

12. A pharmaceutical composition containing a compound or a mixture of compounds according to any one of claims 1 to 9 and a pharmaceutically inert carrier.

13. Compositions according to claim 12 in a form suitable for oral, topical, transdermal, injection, buccal, transmucosal, rectal, pulmonary or inhalation administration, especially in the form of tablets, dragees, capsules, solutions, liquids, gels, plaster, creams, ointments, syrup, slurries, suspensions, spray, nebuliser or suppositories.

14. The use of compounds according to any one of claims 1 to 9 for the manufacture of a medicament as the sole active pharmaceutical ingredient or in combination with other active pharmaceutical ingredients.

15. The use of compounds according to any one of claims 1 to 9 for the manufacture of a medicament for the treatment, prevention or the supportive treatment of diseases or conditions related to the activity of CXCR7 in the area of dermatological disorders, metabolic diseases, inflammatory diseases, fibrotic diseases, infectious diseases, neurological diseases, cardiovascular diseases, respiratory diseases, gastro-intestinal tract disorders, urological diseases, ophthalmic diseases,

~~stomatological diseases, haematological diseases and oncology, or the mobilisation of~~ stem cells,

especially for the manufacture of a medicament for the treatment, prevention or the supportive treatment of diseases or conditions such as HIV infections, Epstein-Barr Virus infection; diabetes mellitus (Type I and/or Type II); conjunctivitis, scleritis, uveitis, rhinosinusitis, Whim syndrome, lupus erythematosus, osteoarthritis, rheumatoid arthritis, synovitis, psoriasis, multiple sclerosis, Crohns disease, inflammatory bowel disease, mixed connective tissue disease, chronic lymphocytic thyroiditis, Graves' disease, graft-versus-host disease, Sjögren's syndrome; dry eye syndrome, glaucoma, age-related macular degeneration; pulmonary arterial hypertension, pulmonary hypoxia, atherosclerosis, myocarditis, heart failure, such as myocardial infarction, arterial thrombosis, stroke, angiogenesis; chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, asthma; sarcoma, such as osteosarcoma, rhabdomyosarcoma, Kaposi's sarcoma, synovial sarcoma; lipoma, such as angiolipoma; glioblastoma multiforme, astrocytomas, neuroblastoma; carcinoma, such as adenocarcinoma; malignant epithelial and mucoepidermoid neoplasms, thyroid neoplasm, gonadal neoplasms, prostate cancer, breast cancer, melanoma, lung carcinoma, pancreatic carcinoma, colorectal cancer; solid tumors; lymphoma, such as Birkitt's lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma; multiple myeloma and leukemia; metastasis; for the inhibition of neointima formation; for stem cell mobilisation of peripheral blood stem cells and/or mesenchymal stem cells; for the mobilisation of endothelial or neuronal progenitor cells; or for different kinds of tissue-repair in human or other mammals.

16. A process for the preparation of compounds according to any one of claims 1 to 9, which comprises

(a) coupling an appropriately functionalized solid support with an appropriately N-protected derivative of that amino acid which in the desired end-product is in position T^1 or T^2 or P^1 to P^4 ~~as defined above; any functional group which may~~

~~be present in said N-protected amino acid derivative being likewise~~ appropriately protected;

(b) removing the N-protecting group from the product obtained in step (a);

(c) coupling the product thus obtained with an appropriately N-protected derivative of that amino acid which in the desired end-product is in the position of the next element (T or P), following counterclockwise or clockwise the sequence according general formula **(I)** in –COOH to $–NH_2$ orientation; any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;

(d) removing the N-protecting group from the product thus obtained;

(e) repeating steps (c) and (d) until all amino acid residues have been introduced;

(f) if desired, selectively deprotecting one or several protected functional group(s) present in the molecule and appropriately substituting the reactive group(s) thus liberated;

(g) detaching the product thus obtained from the solid support;

(h) cyclizing the product cleaved from the solid support;


(i) removing any protecting groups present on functional groups of any members of the chain of amino acid residues and, if desired, any protecting group(s) which may in addition be present in the molecule; and

(j) if desired, implementing additional chemical transformations of one or more reactive group(s) present in the molecule; and/or

(k) if desired, converting the product thus obtained into a pharmaceutically acceptable salt or converting a pharmaceutically acceptable, or unacceptable, salt thus obtained into the corresponding free compound of formula **(I)** or into a different, pharmaceutically acceptable, salt.

CLAIMS

1. Use of a compound of the general formula **(I)**




(I)


wherein the single elements T or P are connected in either direction from the carbonyl (C=O) point of attachment to the nitrogen (N) of the next element and wherein

– either


T^1 is an α-amino acid residue of one of the formulae




AA1




AA2




AA3




AA4




AA5




AA6




AA7



AA8




AA9




AA10

and


T^2 is an α-amino acid residue of one of the formulae




AA11




AA12




AA13




AA14



AA15




AA16




AA17

– or


T^1 is an α-amino acid residue of one of the formulae




AA18




AA19




AA20



AA21




AA22




AA23

and


T^2 is an α-amino acid residue of one of the formulae AA11 to AA17, hereinabove, or an α-amino acid residue of one of the formulae




AA24




AA25




AA26




AA27




AA28




AA29



AA30



AA31




AA32


P^1, P^3 and P^4 are independently

$-NR^1CH(R^{29})CO-$; $-NR^1CH(R^{30})CO-$; or $-NR^1CH(R^{31})CO-$;

P^2 is an α-amino acid residue of one of the formulae



AA33



AA34

A is O; NR^{17}; S; SO; or SO_2;

X is OH; NH_2; OR^{16}; NR^1R^{16}; or $NR^{17}R^{18}$;

Y is NH_2; F; OR^{16}; NR^1R^{16}; or $NR^{17}R^{18}$;

R^1, R^2 and R^3 are independently

H; CF_3; lower alkyl; lower alkenyl; aryl-lower alkyl; or heteroaryl-lower alkyl;

R^4, R^5, R^6, R^7 and R^8 are independently

H; F; CF_3; lower alkyl; lower alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; $-(CHR^{15})_oOR^{17}$; $-(CHR^{15})_oSR^{17}$; $-(CHR^{15})_oNR^{17}R^{18}$; $-(CHR^{15})_oOCONR^{17}R^{18}$; $-(CHR^{15})_oNR^1CONR^{17}R^{18}$; $-(CHR^{15})_oNR^1COR^{17}$; $-(CHR^{15})_oCOOR^{17}$; $-(CHR^{15})_oCONR^{17}R^{18}$; $-(CHR^{15})_oPO(OR^1)_2$; $-(CHR^{15})_oSO_2R^{17}$; $-(CHR^{15})_oNR^1SO_2R^{17}$; $-(CHR^{15})_oSO_2NR^{17}R^{18}$; $-(CR^1R^{15})_oR^{35}$; or $-(CHR^1)_nO(CHR^2)_mR^{35}$; or

R^4 and R^2 taken together can form

=O; $-(CHR^{15})_p-$; $-(CH_2)_nO(CH_2)_m-$; $-(CH_2)_nS(CH_2)_m-$; or $-(CH_2)_nNR^1(CH_2)_m-$; or

R^4 and R^5; R^5 and R^6; R^6 and R^7; R^7 and R^8; or R^6 and R^9 taken together can form:

$-(CHR^{15})_p-$; $-(CH_2)_nO(CH_2)_m-$; $-(CH_2)_nS(CH_2)_m-$; or $-(CH_2)_nNR^1(CH_2)_m-$; or

R^4 and R^5 are independently X;

R^9, R^{10}, R^{11} and R^{12} are independently

H; F; CF_3; lower alkyl; lower alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; $-(CHR^{15})_rOR^{17}$; $-(CHR^{15})_rSR^{17}$; $-(CHR^{15})_rNR^{17}R^{18}$; $-(CHR^{15})_rOCONR^{17}R^{18}$; $-(CHR^{15})_rNR^1CONR^{17}R^{18}$; $-(CHR^{15})_rNR^1COR^{17}$; $-(CHR^{15})_oCOOR^{17}$; $-(CHR^{15})_oCONR^{17}R^{18}$; $-(CHR^{15})_rPO(OR^1)_2$; $-(CHR^{15})_rSO_2R^{17}$; $-(CHR^{15})_rNR^1SO_2R^{17}$; $-(CHR^{15})_rSO_2NR^{17}R^{18}$; $-(CR^1R^{15})_oR^{35}$; or

$-(CHR^1)_rO(CHR^1)_oR^{35}$; or

R^{11} and R^{12} taken together can form

=O; or $=NR^1$;

R^{13} and R^{14} are independently

H; F; Cl; Br; CF_3; OCF_3; $OCHF_2$; CN; NO_2; lower alkyl; lower alkenyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; $-(CHR^{15})_oOR^{17}$; $-(CHR^{15})_oSR^{17}$; $-(CHR^{15})_oNR^{17}R^{18}$; $-(CHR^{15})_oOCONR^{17}R^{18}$; $-(CHR^{15})_oNR^1CONR^{17}R^{18}$; $-(CHR^{15})_oNR^1COR^{17}$; $-(CHR^{15})_oCOOR^{17}$; $-(CHR^{15})_oCONR^{17}R^{18}$; $-(CHR^{15})_oPO(OR^1)_2$; $-(CHR^{15})_oSO_2R^{17}$; $-(CHR^{15})_oNR^1SO_2R^{17}$; $-(CHR^{15})_oSO_2NR^{17}R^{18}$; $-(CR^1R^{15})_oR^{35}$; or $-(CHR^1)_rO(CHR^1)_oR^{35}$;

R^{15} is H; F; CF_3; lower alkyl; lower alkenyl; cycloalkyl; heterocycloalkyl; cycloalkyl-lower alkyl; heterocycloalkyl-lower alkyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; $-(CHR^1)_oOR^{17}$; $-(CHR^1)_oSR^{17}$; $-(CHR^1)_oNR^{17}R^{18}$; $-(CHR^1)_oNR^{20}C(=NR^{19})NR^{17}R^{18}$; $-(CHR^1)_oCOOR^{17}$; $-(CHR^1)_oCONR^{17}R^{18}$; $-(CHR^1)_oSO_2R^{17}$; or $-(CHR^1)_oSO_2NR^{17}R^{18}$;


R^{16} is CF_3; lower alkyl; lower alkenyl; cycloalkyl; heterocycloalkyl; cycloalkyl-lower alkyl; heterocycloalkyl-lower alkyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; cycloalkyl-aryl; heterocycloalkyl-aryl; cycloalkyl-heteroaryl; heterocycloalkyl-heteroaryl; aryl-cycloalkyl; aryl-heterocycloalkyl; heteroaryl-cycloalkyl; heteroaryl-heterocycloalkyl; $-(CHR^1)_sOR^{17}$; $-(CHR^1)_sSR^{17}$; $-(CHR^1)_sNR^{17}R^{18}$; $-(CHR^1)_oCOR^{17}$; $-(CHR^1)_oCOOR^{17}$; $-(CHR^1)_oCONR^{17}R^{18}$; or $-(CHR^1)_oSO_2R^{17}$;

R^{17}, R^{18}, R^{19} and R^{20} are independently


H; lower alkyl; lower alkenyl; lower alkoxy; cycloalkyl; heterocycloalkyl; cycloalkyl-lower alkyl; heterocycloalkyl-lower alkyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; cycloalkyl-aryl; heterocycloalkyl-aryl; cycloalkyl-heteroaryl; heterocycloalkyl-heteroaryl; aryl-cycloalkyl; aryl-heterocycloalkyl; heteroaryl-cycloalkyl; or heteroaryl-heterocycloalkyl; or the structural elements $-NR^{17}R^{18}$ and $-NR^{19}R^{20}$ can independently form:

heterocycloalkyl; aryl-heterocycloalkyl; or heteroaryl-heterocycloalkyl;


or a group of one of the formulae




C1




C2




C3




C4




C5



C6



C7



C8

Z, Z' and Z'' are independently

$-CR^{39}$; or N;

R^{21}, R^{22}, R^{23} and R^{24} are independently

H; F; CF_3; lower alkyl; lower alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; $-(CHR^1)_oOR^{17}$; $-(CHR^1)_oSR^{17}$; $-(CHR^1)_oNR^2R^{17}$; $-(CHR^1)_oOCONR^2R^{17}$; $-(CHR^1)_oNR^2CONR^3R^{17}$; $-(CHR^1)_oNR^2COR^{17}$; $-(CHR^1)_oCOOR^{17}$; $-(CHR^1)_oCONR^2R^{17}$; $-(CHR^1)_oPO(OR^2)_2$; $-(CHR^1)_oSO_2R^{17}$; $-(CHR^1)_oNR^2SO_2R^{17}$; $-(CHR^1)_oSO_2NR^2R^{17}$; $-(CR^1R^2)_oR^{38}$; or $-(CHR^1)_nO(CHR^2)_mR^{38}$;

R^{25} and R^{26} are independently

H; F; CF_3; lower alkyl; lower alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; $-(CHR^1)_rOR^{17}$; $-(CHR^1)_rSR^{17}$; $-(CHR^1)_rNR^2R^{17}$; $-(CHR^1)_rOCONR^2R^{17}$; $-(CHR^1)_rNR^2CONR^3R^{17}$;$-(CHR^1)_rNR^2COR^{17}$; $-(CHR^1)_oCOOR^{17}$; $-(CHR^1)_oCONR^2R^{17}$; $-(CHR^1)_rPO(OR^2)_2$; $-(CHR^1)_rSO_2R^{17}$; $-(CHR^1)_rNR^2SO_2R^{17}$; $-(CHR^1)_rSO_2NR^2R^{17}$; $-(CR^1R^2)_oR^{38}$; or $-(CHR^1)_rO(CHR^2)_oR^{38}$;

R^{27} is H; F; Cl; Br; CF_3; OCF_3; $OCHF_2$; CN; NO_2; lower alkyl; lower alkenyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; $-(CHR^1)_oOR^{17}$; $-(CHR^1)_oSR^{17}$; $-(CHR^1)_oNR^2R^{17}$; $-(CHR^1)_oOCONR^2R^{17}$; $-(CHR^1)_oNR^2CONR^3R^{17}$; $-(CHR^1)_oNR^2COR^{17}$; $-(CHR^1)_oCOOR^{17}$; $-(CHR^1)_oCONR^2R^{17}$; $-(CHR^1)_oPO(OR^2)_2$; $-(CHR^1)_oSO_2R^{17}$; $-(CHR^1)_oNR^2SO_2R^{17}$; $-(CHR^1)_oSO_2NR^2R^{17}$; $-(CR^1R^2)_oR^{38}$; or $-(CHR^1)_rO(CHR^2)_oR^{38}$;

R^{29} is H; alkyl; alkenyl; cycloalkyl-lower alkyl; heterocycloalkyl-lower alkyl; $-(CHR^4)_oOR^{17}$; $-(CHR^4)_oSR^{17}$; or $-(CHR^4)_rNR^{17}R^{18}$;

R^{30} is $-(CR^1R^4)_nR^{35}$; $-(CH_2)_nO(CH_2)_mR^{35}$; $-(CH_2)_nS(CH_2)_mR^{35}$; or $-(CH_2)_nNR^1(CH_2)_mR^{35}$;


R^{31} is alkyl; alkenyl; $-(CR^1R^{15})_qNR^{17}R^{18}$; $-(CR^1R^{15})_qNR^2R^{16}$; $-(CR^1R^{15})_qNR^{17}R^{32}$; $-(CR^1R^{15})_qNR^{17}COR^{18}$; $-(CH_2)_qC(=NR^{15})NR^{17}R^{18}$; $-(CH_2)_qC(=NOR^{19})NR^{17}R^{18}$; $-(CH_2)_qC(=NNR^{17}R^{18})NR^{19}R^{20}$; $-(CR^1R^{15})_qNR^{20}C(=NR^{19})NR^{17}R^{18}$; $-(CR^1R^{15})_qN=C(NR^{17}R^{18})NR^{19}R^{20}$; $-(CR^1R^{15})_qOR^{17}$; $-(CR^1R^{15})_qOR^{32}$; $-(CR^1R^{15})_qSR^{17}$; $-(CR^1R^{15})_qSO_2R^{17}$; $-(CR^1R^{15})_qNR^{17}SO_2R^{18}$; $-(CR^1R^{15})_qSO_2NR^2R^{16}$; $-(CR^1R^{15})_qSO_2NR^{17}R^{18}$; $-(CR^1R^{15})_qNR^{19}SO_2NR^{17}R^{18}$; $-(CR^1R^{15})_qPO(OR^2)_2$; $-(CH_2)_nO(CH_2)_mNR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mC(=NR^{19})NR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mC(=NOR^{19})NR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mC(=NNR^{17}R^{18})NR^{19}R^{20}$; $-(CH_2)_nO(CH_2)_mNR^{20}C(=NR^{19})NR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mN=C(NR^{17}R^{18})NR^{19}R^{20}$; $-(CH_2)_nS(CH_2)_mNR^{17}R^{18}$; $-(CH_2)_nS(CH_2)_mC(=NR^{19})NR^{17}R^{18}$; $-(CH_2)_nS(CH_2)_mC(=NOR^{19})NR^{17}R^{18}$; $-(CH_2)_nS(CH_2)_mC(=NNR^{17}R^{18})NR^{19}R^{20}$; $-(CH_2)_nS(CH_2)_mNR^{20}C(=NR^{19})NR^{17}R^{18}$; $-(CH_2)_nS(CH_2)_mN=C(NR^{17}R^{18})NR^{19}R^{20}$; $-(CR^1R^{15})_qCOOR^{17}$; $-(CR^1R^{15})_qCONR^{17}R^{18}$; or $-(CR^1R^{15})_qCOR^{33}$;

R^{32} is $-COR^{29}$; $-COR^{30}$; $-CO(CR^1R^{15})_oR^{17}$; $-CO(CR^1R^{15})_oOR^{17}$; $-CO(CR^1R^{15})_oNR^{17}R^{18}$; $-CO(CR^1R^{15})_oNR^2R^{16}$; $-CO(CR^1R^{29})NR^{17}R^{18}$; $-CO(CR^1R^{30})NR^{17}R^{18}$; $-CO(CR^1R^{34})NR^{17}R^{18}$; $-CO(CHR^1)_oCONR^{17}R^{18}$; $-CO(CHR^1)_oCONR^{17}SO_2R^{18}$; $-CO(CR^1R^{15})_oNR^{17}SO_2R^{18}$; $-CONR^1(CHR^{17})_nNR^2(CHR^{15})_mR^{16}$; $-CO(CHR^{17})_nO(CHR^{15})_mR^{16}$; $-CONR^1(CHR^{17})_nO(CHR^{15})_mR^{16}$; $-SO_2R^{29}$; $-SO_2R^{30}$; $-SO_2(CR^1R^{15})_oR^{17}$; or $-SO_2(CR^1R^{15})_oNR^{17}R^{18}$;


R^{33} is $-NR^1C(R^2)(R^{29})COOR^{17}$; $-NR^1C(R^2)(R^{29})CONR^{17}R^{18}$; $-NR^1C(R^2)(R^{30})COOR^{17}$; $-NR^1C(R^2)(R^{30})CONR^{17}R^{18}$; $-NR^1C(R^2)(R^{34})COOR^{17}$; or $-NR^1C(R^2)(R^{34})CONR^{17}R^{18}$;

R^{34} is $-(CR^1R^{15})_qNR^{17}R^{18}$; $-(CH_2)_qC(=NR^{19})NR^{17}R^{18}$; $-(CH_2)_qC(=NOR^{19})NR^{17}R^{18}$; $-(CH_2)_qC(=NNR^{17}R^{18})NR^{19}R^{20}$; $-(CR^1R^{15})_qNR^2C(=NR^{19})NR^{17}R^{18}$; $-(CR^1R^{15})_qN=C(NR^{17}R^{18})NR^{19}R^{20}$; $-(CR^1R^{15})_qOR^{17}$; $-(CR^1R^{15})_qSR^{17}$; $-(CR^1R^{15})_qSO_2R^{17}$; $-(CR^1R^{15})_qNR^{17}SO_2R^{18}$; $-(CR^1R^{15})_qSO_2NR^1R^{16}$; $-(CR^1R^{15})_qSO_2NR^{17}R^{18}$; $-(CR^1R^{15})_qNR^2SO_2NR^{17}R^{18}$; $-(CR^1R^{15})_qPO(OR^1)_2$; $-(CH_2)_nO(CH_2)_mNR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mC(=NR^{19})NR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mC(=NOR^{19})NR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mC(=NNR^{17}R^{18})NR^{19}R^{20}$; $-(CH_2)_nO(CH_2)_mNR^{20}C(=NR^{19})NR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mN=C(NR^{17}R^{18})NR^{19}R^{20}$; $-(CH_2)_nS(CH_2)_mNR^{17}R^{18}$; $-(CH_2)_nS(CH_2)_mC(=NR^{19})NR^{17}R^{18}$; $-(CH_2)_nS(CH_2)_mC(=NOR^{19})NR^{17}R^{18}$; $-(CH_2)_nS(CH_2)_mC(=NNR^{17}R^{18})NR^{19}R^{20}$; $-(CH_2)_nS(CH_2)_mNR^{20}C(=NR^{19})NR^{17}R^{18}$; $-(CH_2)_nS(CH_2)_mN=C(NR^{17}R^{18})NR^{19}R^{20}$; $-(CR^1R^{15})_qCOOR^{17}$; or $-(CR^1R^{15})_qCONR^{17}R^{18}$;


R^{35} is an aryl group of one of the formulae



AR1




AR2




AR3


or a heteroaryl group of one of the formulae




H1




H2




H3




H4




H5




H6




H7




H8




H9




H10




H11




H12




H13




H14




H15




H16




H17




H18




H19




H20




H21




H22




H23




H24




H25




H26




H27




H28




H29




H30




H31




H32




H33




H34




H35




H36




H37




H38




H39




H40




H41




H42




H43




H44




H45




H46




H47




H48



H49



H50




H51

R^{36} and R^{37} are independently

H; F; Cl; Br; CF_3; OCF_3; $OCHF_2$; CN; NO_2; lower alkyl; lower alkenyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; $-(CH_2)_oR^{38}$; $-(CH_2)_oOR^{17}$; $-O(CH_2)_oR^{38}$; $-(CH_2)_oSR^{17}$; $-(CH_2)_oNR^{17}R^{18}$; $-(CH_2)_oOCONR^{17}R^{18}$; $-(CH_2)_oNR^1CONR^{17}R^{18}$; $-(CH_2)_oNR^1COR^{17}$; $-(CH_2)_oCOOR^{17}$; $-(CH_2)_oCONR^{17}R^{18}$; $-(CH_2)_oPO(OR^1)_2$; $-(CH_2)_oSO_2R^{16}$; or $-(CH_2)_oCOR^{17}$;

R^{38} is an aryl group of the formula



AR4

R^{39}, R^{40} and R^{41} are independently

H; F; Cl; Br; OH; NH_2; NO_2; CN; CF_3; $OCHF_2$; OCF_3; $-NR^1R^{17}$; $-(CH_2)_oCOOR^{17}$; $-(CH_2)_oCONR^1R^{17}$; lower alkyl; lower alkoxy; or lower alkenyl;

R^{42} is H; lower alkyl; or aryl-lower alkyl;

n and m are independently an integer of 0-5 with the proviso that $n+m \leq 6$;

o is 0-4; p is 2-6; q is 1-6; r is 1-3; s is 0-4;

or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disease or condition related to the activity of CXCR7.

2. The use according to claim 1 wherein

R^{16} is CF_3; lower alkyl; lower alkenyl; cycloalkyl; heterocycloalkyl; cycloalkyl-lower alkyl; heterocycloalkyl-lower alkyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; $-(CHR^1)_sOR^{17}$; $-(CHR^1)_sSR^{17}$; $-(CHR^1)_sNR^{17}R^{18}$; $-(CHR^1)_oCOR^{17}$; $-(CHR^1)_oCOOR^{17}$; $-(CHR^1)_oCONR^{17}R^{18}$; or $-(CHR^1)_oSO_2R^{17}$;

R^{17}, R^{18}, R^{19} and R^{20} are independently H; lower alkyl; lower alkenyl; lower alkoxy; cycloalkyl; heterocycloalkyl; cycloalkyl-lower alkyl; heterocycloalkyl-lower alkyl; aryl; heteroaryl; aryl-lower alkyl; or heteroaryl-lower alkyl; or

the structural elements $-NR^{17}R^{18}$ and $-NR^{19}R^{20}$ can independently form: heterocycloalkyl; aryl-heterocycloalkyl; or heteroaryl-heterocycloalkyl; or a group of one of the above formulae C1 to C8;

R^{31} is alkyl; alkenyl; $-(CR^1R^{15})_qNR^{17}R^{18}$; $-(CR^1R^{15})_qNR^2R^{16}$; $-(CR^1R^{15})_qNR^{17}COR^{18}$; $-(CH_2)_qC(=NR^{15})NR^{17}R^{18}$; $-(CR^1R^{15})_qNR^{20}C(=NR^{19})NR^{17}R^{18}$; $-(CR^1R^{15})_qOR^{17}$; $-(CR^1R^{15})_qSR^{17}$; $-(CR^1R^{15})_qSO_2R^{17}$; $-(CR^1R^{15})_qNR^{17}SO_2R^{18}$; $-(CR^1R^{15})_qSO_2NR^2R^{16}$; $-(CR^1R^{15})_qSO_2NR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mNR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mC(=NR^{19})NR^{17}R^{18}$; $-(CH_2)_nO(CH_2)_mNR^{20}C(=NR^{19})NR^{17}R^{18}$; $-(CH_2)_nS(CH_2)_mNR^{17}R^{18}$; $-(CH_2)_nS(CH_2)_mNR^{20}C(=NR^{19})NR^{17}R^{18}$; $-(CR^1R^{15})_qCONR^{17}R^{18}$; or $-(CR^1R^{15})_qCOR^{33}$;

s is 2-4.

3. The use according to claim 1 wherein

T^1 is ^{D}Pro; ^{D}Pip; ^{D}Tic; ^{D}Tiq; ^{D}Oic; ^{D}Azt; ^{D}Pro((3*R*)OH); ^{D}Pro((3*S*)OH); ^{D}Pro((3*R*)NH_2); ^{D}Pro((3*S*)NH_2); ^{D}Pro((4*R*)OH); ^{D}Pro((4*S*)OH); ^{D}Pro((4*R*)NH_2); ^{D}Pro((4*S*)NH_2); ^{D}Pro((4*S*)NHBz); or ^{D}Mor;

T^2 is Thr; *allo*Thr; Ser; hSer; Pro((3*R*)OH); Pro((3*S*)OH); Hyp(Bn); (4*S*)-Hyp(Bn); Pro((3*R*)NH_2); Pro((3*S*)NH_2); Pro((4*R*)NH_2); Pro((4*S*)NH_2); Pro((4*S*)F); Pro((4*S*)NHBz); or Mor; or

when T^1 is ^{D}Pro((3*R*)OH); ^{D}Pro((3*S*)OH); ^{D}Pro((3*R*)NH_2); ^{D}Pro((3*S*)NH_2); ^{D}Pro((4*R*)NH_2); ^{D}Pro((4*S*)NH_2); ^{D}Pro((4*S*)NHBz); or ^{D}Mor

then T^2 can in addition be

Pro; Pip; Tic; Tiq; Oic; or Azt;

P^1, P^3 and P^4 are independently

Ala; Arg; Asn; Asp; Cit; Cys; Glu; Gln; Gly; His; Ile; Leu; Lys; Met; Orn; Phe; Pro; Ser; Thr; Trp; Tyr; Val; Abu; Agb; Agp; Ala(*t*Bu); Ala(*c*Pr); Ala(2Furyl); Ala(3Furyl); Ala(Ppz); Ala(1Pyraz); Ala(2Quin); Ala(3Quin); Ala(4Quin); Ala(Tet); Azt; Bbta; Bip; Cha; Chg; Dab; Dab(Ac); Dab(*c*Pr); Dab(*i*Pr); Dab(4Me_2NPhSO_2); Dab(MeOEtNCO); Dab(MePpzCO); Dab(MeSO_2); Dab(morphCO); Dab(1Nal); Dab(2Nal); Dap; Dap($CONH_2$); Dap(MeOEt); Dap((MeOEt)$_2$); Deg; Gly(*t*Bu); hArg; hCha; hCys; hHis; hLys; hPhe; hSer; hSer(Me); hTrp; hTyr; His(Me); His(Bn); Hyp(Bn); (4*S*)-Hyp(Bn); Hyp(4BrBn); Hyp(3CNBn); Hyp(4CNBn); Hyp(CONHPh); Hyp(Ph); Lys(Ac); Lys(Bz); Lys(*c*Pr); Lys(*i*Pr); Lys(Me); Lys(Nic); Lys((5*R*)OH); Lys(4Oxa); Met(O_2); 1Nal; 2Nal; Nle; Nle(6OBn); OctG; Oic; Orn(*c*Pr); Orn(*i*Pr); 2Pal; 3Pal; 4Pal; Phe(2Cl); Phe(3Cl); Phe(4Cl); Phe(3,4Cl_2); Phe(2F); Phe(3F); Phe(4F); Phe(4CN); Phe(4CF_3); Phe(4COOMe); Phg; Pip; Pro((4*R*)Bn); Pro((4*S*)F); Pro((4*S*)*c*Hex); Pro(5,5Me_2); Ser(Bn); Ser(Me); Thi; *allo*Thr; Thr(Bn); Thz; Thz(5,5Me_2); Tic; Tic(7OH); Trp(7Aza); Trp(5Br); Trp(6Br); Trp(6CF_3); Trp(5Cl); Trp(6Cl); Trp(5,6Cl); Trp(5OH); Tyr(Bn); Tyr(Me); Tyr(4MeOCOBn); Tyr(Ph); Tyr(4OHPh); Tza; Gln(Alk1); Gln(Alk2); Gln(Alk3); Gln(Alk4); Gln(Alk5); Gln(Alk6); Gln(Alk7); Gln(Alk8); Gln(Alk9); Gln(Alk10); Gln(Alk11); Gln(Alk12); Gln(Alk13); Gln(Alk14); Gln(Alk15); Gln(Alk16); Gln(Alk17); Gln(Alk18); Gln(Alk19); Gln(Alk20); Gln(Alk21); Gln(Alk22); Gln(Alk23); Gln(Alk24); Gln(Alk25); Gln(Alk26); Gln(Alk27); Gln(Alk28); Gln(Alk29); Gln(Alk30); Gln(Alk31); Gln(Alk32); Gln(Alk33); Gln(Alk34); Glu(cN1); Glu(cN2); Glu(cN3); Glu(cN4); Glu(cN5); Glu(cN6); Glu(cN7); Glu(cN8); Glu(cN9); Glu(cN10); Glu(cN11); Glu(cN12); Glu(cN13); Glu(cN14); Glu(cN15); Glu(cN16); Glu(cN17); Lys(Ar1); Lys(Ar2); Lys(Ar3); Lys(Ar4); Lys(Ar5); Lys(Ar6); Lys(Ar7); Lys(Ar8); Lys(Ar9); Lys(Ar10); Lys(Ar11); Lys(Ar12); Orn(Ar1); Orn(Ar2); Orn(Ar3); Orn(Ar4); Orn(Ar5); Orn(Ar6); Orn(Ar7); Orn(Ar8); Orn(Ar9); Orn(Ar10); Orn(Ar11);

Orn(Ar12); Dab(Ar1); Dab(Ar2); Dab(Ar3); Dab(Ar4); Dab(Ar5); Dab(Ar6); Dab(Ar7); Dab(Ar8); Dab(Ar9); Dab(Ar10); Dab(Ar11); Dab(Ar12); Dab(S1); Dab(S2); Dab(S3); Dab(S4); Dab(S5); Dab(S6); Dab(S7); Dab(S8); Dab(S9); Dab(S10); Dab(S11); Dab(S12); Dab(S13); Dab(S14); Dab(S15); Dab(S16); Dab(S17); Dab(S18); Dab(A1); Dab(A2); Dab(A3); Dab(A4); Dab(A5); Dab(A6); Dab(A7); Dab(A8); Dab(A9); Dab(A10); Dab(A11); Dab(A12); Dab(A13); Dab(A14); Dab(A15); Dab(A16); Dab(A17); Dab(A18); Dab(A19); Dab(A20); Dab(A21); Dab(A22); Dab(A23); Dab(A24); Dab(A25); Dab(A26); Dab(A27); Dab(A28); Dab(A29); Dab(A30); Dab(A31); Dab(A32); Dab(A33); Dab(A34); Dab(A35); Dab(A36); Dab(A37); Dab(A38); Dab(A39); Dab(A40); Dab(A41); Dab(A42); Dab(A43); Dab(A44); Dab(A45); Dab(A46); Dab(A47); Dab(A48); Dab(A49); Dab(A50); Dab(A51); Dab(A52); Dab(A53); Dab(A54); Dab(A55); Orn(A1); Orn(A2); Orn(A3); Orn(A4); Orn(A5); Orn(A6); Orn(A7); Orn(A8); Orn(A9); Orn(A10); Orn(A11); Orn(A12); Orn(A13); Orn(A14); Orn(A15); Orn(A16); Orn(A17); Orn(A18); Orn(A19); Orn(A20); Orn(A21); Orn(A22); Orn(A23); Orn(A24); Orn(A25); Orn(A26); Orn(A27); Orn(A28); Orn(A29); Orn(A30); Orn(A31); Orn(A32); Orn(A33); Orn(A34); Orn(A35); Orn(A36); Orn(A37); Orn(A38); Orn(A39); Orn(A40); Orn(A41); Orn(A42); Orn(A43); Orn(A44); Orn(A45); Orn(A46); Orn(A47); Orn(A48); Orn(A49); Orn(A50); Orn(A51); Orn(A52); Orn(A53); Orn(A54); Orn(A55); Orn(A56); Asn(Alk1); Asn(Alk2); Asn(Alk3); Asn(Alk4); Asn(Alk5); Asn(Alk6); Asn(Alk7); Asn(Alk8); Asn(Alk9); Asn(Alk10); Asn(Alk11); Asn(Alk12); Asn(Alk13); Asn(Alk14); Asn(Alk15); Asn(Alk16); Asn(Alk17); Asn(Alk18); Asn(Alk19); Asn(Alk20); Asn(Alk21); Asn(Alk22); Asn(Alk23); Asn(Alk24); Asn(Alk25); Asn(Alk26); Asn(Alk27); Asn(Alk28); Asn(Alk29); Asn(Alk30); Asn(Alk31); Asn(Alk32); Asn(Alk33); Asn(Alk34); Asp(cN1); Asp(cN2); Asp(cN3); Asp(cN4); Asp(cN5); Asp(cN6); Asp(cN7); Asp(cN8); Asp(cN9); Asp(cN10); Asp(cN11); Asp(cN12); Asp(cN13); Asp(cN14); Asp(cN15); Asp(cN16); Asp(cN17); Dap(Ar1); Dap(Ar2); Dap(Ar3); Dap(Ar4); Dap(Ar5); Dap(Ar6); Dap(Ar7); Dap(Ar8); Dap(Ar9); Dap(Ar10); Dap(Ar11); Dap(Ar12); Dap(S1); Dap(S2); Dap(S3); Dap(S4); Dap(S5);

Dap(S6); Dap(S7); Dap(S8); Dap(S9); Dap(S10); Dap(S11); Dap(S12); Dap(S13); Dap(S14); Dap(S15); Dap(S16); Dap(S17); Dap(S18); Dap(A1); Dap(A2); Dap(A3); Dap(A4); Dap(A5); Dap(A6); Dap(A7); Dap(A8); Dap(A9); Dap(A10); Dap(A11); Dap(A12); Dap(A13); Dap(A14); Dap(A15); Dap(A16); Dap(A17); Dap(A18); Dap(A19); Dap(A20); Dap(A21); Dap(A22); Dap(A23); Dap(A24); Dap(A25); Dap(A26); Dap(A27); Dap(A28); Dap(A29); Dap(A30); Dap(A31); Dap(A32); Dap(A33); Dap(A34); Dap(A35); Dap(A36); Dap(A37); Dap(A38); Dap(A39); Dap(A40); Dap(A41); Dap(A42); Dap(A43); Dap(A44); Dap(A45); Dap(A46); Dap(A47); Dap(A48); Dap(A49); Dap(A50); Dap(A51); Dap(A52); Dap(A53); Dap(A54); or Dap(A55);

P^2 is ^{D}Arg; ^{D}hArg; ^{D}Agb; ^{D}Lys; ^{D}Orn; ^{D}Cit; ^{D}Thr; ^{D}Dab; ^{D}Dab; ^{D}Phe; ^{D}Phe(4CF_3); ^{D}Trp; ^{D}His; ^{D}Tyr; ^{D}2Pal; ^{D}3Pal; ^{D}4Pal; ^{D}Lys(Ar1); ^{D}Lys(Ar2); ^{D}Lys(Ar3); ^{D}Lys(Ar4); ^{D}Lys(Ar5); ^{D}Lys(Ar6); ^{D}Lys(Ar7); ^{D}Lys(Ar8); ^{D}Lys(Ar9); ^{D}Lys(Ar10); ^{D}Lys(Ar11); ^{D}Lys(Ar12); ^{D}Orn(A41); ^{D}Orn(A56); ^{D}Orn(Ar1); ^{D}Orn(Ar2); ^{D}Orn(Ar3); ^{D}Orn(Ar4); ^{D}Orn(Ar5); ^{D}Orn(Ar6); ^{D}Orn(Ar7); ^{D}Orn(Ar8); ^{D}Orn(Ar9); ^{D}Orn(Ar10); ^{D}Orn(Ar11); ^{D}Orn(Ar12); ^{D}Dab(Ar1); ^{D}Dab(Ar2); ^{D}Dab(Ar3); ^{D}Dab(Ar4); ^{D}Dab(Ar5); ^{D}Dab(Ar6); ^{D}Dab(Ar7); ^{D}Dab(Ar8); ^{D}Dab(Ar9); ^{D}Dab(Ar10); ^{D}Dab(Ar11); ^{D}Dab(Ar12); ^{D}Dap(Ar1); ^{D}Dap(Ar2); ^{D}Dap(Ar3); ^{D}Dap(Ar4); ^{D}Dap(Ar5); ^{D}Dap(Ar6); ^{D}Dap(Ar7); ^{D}Dap(Ar8); ^{D}Dap(Ar9); ^{D}Dap(Ar10); ^{D}Dap(Ar11); or ^{D}Dap(Ar12).

4. The use according to claim 1 wherein

T^1 is ^{D}Pro; ^{D}Pip; ^{D}Tic; ^{D}Tiq; ^{D}Oic; ^{D}Azt; ^{D}Pro((3*R*)OH); ^{D}Pro((3*S*)OH); ^{D}Pro((3*R*)NH_2); ^{D}Pro((3*S*)NH_2); ^{D}Pro((4*R*)OH); ^{D}Pro((4*S*)OH); ^{D}Pro((4*R*)NH_2); ^{D}Pro((4*S*)NH_2); ^{D}Pro((4*S*)NHBz); or ^{D}Mor;

T^2 is Thr; *allo*Thr; Ser; hSer; Pro((3*R*)OH); Pro((3*S*)OH); Hyp(Bn); (4*S*)-Hyp(Bn); Pro((3*R*)NH_2); Pro((3*S*)NH_2); Pro((4*R*)NH_2); Pro((4*S*)NH_2); Pro((4*S*)F); Pro((4*S*)NHBz); or Mor; or

when T^1 is ^{D}Pro((3*R*)OH); ^{D}Pro((3*S*)OH); ^{D}Pro((3*R*)NH_2); ^{D}Pro((3*S*)NH_2); ^{D}Pro((4*R*)NH_2); ^{D}Pro((4*S*)NH_2); ^{D}Pro((4*S*)NHBz); or ^{D}Mor

then T^2 can in addition be

Pro; Pip; Tic; Tiq; Oic; or Azt;

P^1 is Ile; Nle; Leu; Val; Chg; Cha; Abu; Ala; Ala(*c*Pr); Ala(1Pyraz); Ala(Tet); Trp; 1Nal; 2Nal; Phe; Tyr; 2Pal; 3Pal; 4Pal; Thr; His; Arg; hArg; Agb; Pip; Orn(Ar2); or Orn(A56);

P^2 is ^{D}Arg; ^{D}hArg; ^{D}Agb; ^{D}Lys; ^{D}Orn; ^{D}Cit; ^{D}Thr; ^{D}Dab; ^{D}Dap; ^{D}Phe; ^{D}Trp; ^{D}His; ^{D}Tyr; ^{D}2Pal; ^{D}3Pal; or ^{D}4Pal;

P^3 is Arg; hArg; Agb; Agp; Lys; Orn; Orn(A41); Orn(A56); Orn(Ar2); Orn(Ar4); Orn(Ar7); Cit; Thr; Dab; Dap; Phe; Trp; His; Tyr; or Ile

P^4 is Trp; His; Phe; Phe($4CF_3$); 1Nal; 2Nal; Tyr; Leu; Ile; Arg; hArg; Lys; Dab; Dap; Orn; Orn(A56); or Orn(Ar7).

5. The use according to claim 1 wherein

T^1 is ^{D}Pro; ^{D}Pip; ^{D}Tic; ^{D}Pro((4*S*)OH); ^{D}Pro((4*R*)NH_2); or ^{D}Pro((4*S*)NH_2);

T^2 is Thr; *allo*Thr; Ser; hSer; Pro((3*S*)OH); (4*S*)-Hyp(Bn); Pro((4*R*)NH_2); Pro((4*S*)NH_2); Pro((4*S*)F); Pro((4*S*)NHBz); or Mor;

P^1 is Ile; Nle; Leu; Val; Chg; Cha; Abu; Ala; Trp; 1Nal; Tyr; 3Pal; Thr; His; Arg; hArg; Agb; Pip; Ala(1Pyraz); Ala(Tet); Orn(Ar2); or Orn(A56);

P^2 is ^{D}Arg; ^{D}Lys; ^{D}Orn; ^{D}Cit; ^{D}Thr; ^{D}Dab; ^{D}Phe; ^{D}Trp; ^{D}His; or ^{D}3Pal;

P^3 is Arg; hArg; Agb; Agp; Lys; Orn; Orn(A41); Orn(A56); Orn(Ar2); Orn(Ar4); Orn(Ar7); Dab; Trp; or His;

P^4 is Trp; His; Phe; Phe($4CF_3$); 1Nal; 2Nal; Tyr; Ile; Arg; hArg; Lys; Dab; Orn; Orn(A56); or Orn(Ar7).

6. The use according claim 1, wherein the compound of formula **(I)** is selected from

cyclo(-Ile-^{D}Arg-Arg-Ile-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Arg-Tyr-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Lys-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Dab-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Dab-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Arg-Phe-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Thr-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pro-hSer-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pro-*allo*Thr-);

cyclo(-1Nal-^{D}Arg-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Lys-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}His-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Cit-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pip-Thr-);

cyclo(-Ile-^{D}Arg-Arg-2Nal-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Arg-1Nal-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Trp-Arg-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Thr-^{D}Arg-Trp-Arg-^{D}Pro-Thr-);

cyclo(-Trp-^{D}Arg-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pro-Pro((3*S*)OH)-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pro-Ser-);

cyclo(-Ile-^{D}Arg-Agp-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Agb-Trp-^{D}Pro-Thr-);

cyclo(-Trp-^{D}Phe-Trp-Arg-^{D}Pro((4*S*)NH_2)-Tic-);

cyclo(-Trp-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Ala-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Tyr-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Trp-^{D}Phe-Trp-Orn-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Trp-^{D}Phe-Trp-Dab-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Trp-^{D}Phe-Trp-Lys-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Trp-^{D}Phe-Trp-His-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Arg-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Pip-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-hArg-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Agb-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-3Pal-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Trp-^{D}3Pal-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Arg-^{D}Phe-Trp-hArg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Arg-^{D}Phe-Trp-Arg-^{D}Pro((4*S*)NH_2)-Tic-);

cyclo(-Trp-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Oic-);

cyclo(-Arg-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Oic-);

cyclo(-Trp-^{D}Phe-Trp-Arg-^{D}Pro-Pro((4*S*)F)-);

cyclo(-Trp-^{D}Phe-Trp-Arg-^{D}Pro-Pro((4*S*)NH_2)-);

cyclo(-Trp-^{D}Phe-Trp-Arg-^{D}Pro-Pro((4*R*)NH_2)-);

cyclo(-Trp-^{D}Phe-Trp-Arg-^{D}Pro-Mor-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pro-Mor-);

cyclo(-Arg-^{D}Phe-Trp-Arg-^{D}Pro-(4*S*)-Hyp(Bn)-);

cyclo(-Trp-^{D}Phe-Trp-Arg-^{D}Pro((4*S*)OH)-(4*S*)-Hyp(Bn)-);

cyclo(-Trp-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-(4*S*)-Hyp(Bn)-);

cyclo(-His-^{D}Trp-His-Trp-^{D}Pro- Pro((4*S*)NHBz)-);

cyclo(-1Nal-^{D}Arg-Arg-Trp-^{D}Pro-Pro((3*S*)OH)-);

cyclo(-Ile-^{D}Arg-Arg-2Nal-^{D}Pro-Pro((3*S*)OH)-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pip-Pro((3*S*)OH)-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pro((4*S*)OH)-Thr-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pro((4*R*)NH_2)-Thr-);

cyclo(-Val-^{D}Arg-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Abu-^{D}Arg-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Chg-^{D}Arg-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Leu-^{D}Arg-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Nle-^{D}Arg-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Cha-^{D}Arg-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Orn-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Orn(A41)-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Orn-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-hArg-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Tic-Thr-);

cyclo(-Ile-^{D}Arg-Orn(Ar2)-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Orn(Ar7)-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Orn(Ar4)-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Orn(A56)-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Arg-Phe(4CF_3)-^{D}Pro-Thr-);

cyclo(-Trp-^{D}Phe-Trp-Orn(A56)-^{D}Pip-Pro((3*S*)OH)-);

cyclo(-Ala(1Pyraz)-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Ala(Tet)-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Orn(Ar2)-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Orn(A56)-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Trp-^{D}Phe-Trp-Orn(Ar7)-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Trp-^{D}Phe-Trp-Orn(A56)-^{D}Pro((4*R*)NH_2)-Tiq-);

cyclo(-Trp-^{D}Phe-Trp-Orn(A56)-^{D}Pro((4*R*)NH_2)-Tic-);

and pharmaceutically acceptable salts thereof.

7. The use according claim 6, wherein the compound of formula **(I)** is selected from

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pip-Thr-);

cyclo(-Ile-^{D}Arg-Arg-2Nal-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pro-Ser-);

cyclo(-Trp-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Trp-^{D}Phe-Trp-Dab-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-3Pal-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Trp-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Oic-);

cyclo(-Trp-^{D}Phe-Trp-Arg-^{D}Pro((4*S*)OH)-(4*S*)-Hyp(Bn)-);

cyclo(-Ile-^{D}Arg-Arg-Trp-^{D}Pip-Pro((3*S*)OH)-);

cyclo(-Chg-^{D}Arg-Arg-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-hArg-Trp-^{D}Pro-Thr-);

and pharmaceutically acceptable salts thereof.

8. The use according claim 6, wherein the compound of formula **(I)** is selected from

cyclo(-Ile-^{D}Arg-Orn(Ar2)-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Orn(Ar7)-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Orn(Ar4)-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Orn(A56)-Trp-^{D}Pro-Thr-);

cyclo(-Ile-^{D}Arg-Arg-Phe(4CF_3)-^{D}Pro-Thr-);

cyclo(-Trp-^{D}Phe-Trp-Orn(A56)-^{D}Pip-Pro((3*S*)OH)-);

cyclo(-Ala(1Pyraz)-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Ala(Tet)-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Orn(Ar2)-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Orn(Ar56)-^{D}Phe-Trp-Arg-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Trp-^{D}Phe-Trp-Orn(Ar7)-^{D}Pro((4*R*)NH_2)-Tic-);

cyclo(-Trp-^{D}Phe-Trp-Orn(A56)-^{D}Pro((4*R*)NH_2)-Tiq-);

cyclo(-Trp-^{D}Phe-Trp-Orn(A56)-^{D}Pro((4*R*)NH_2)-Tic-);

and pharmaceutically acceptable salts thereof.

9. The use according to any one of claims 1 to 8, wherein the compound of formula **(I)** is an epimer or a diastereomer based on one or more chiral centers not explicitly specified in formula **(I)**.

10. The use of a compound of formula **(I)** as defined in any one of claims 1 to 9 in the manufacture of a medicament for the treatment of a disease or condition treatable by modulating activity against the CXCR7 receptor.

11. The use according to claim 10, wherein the disease or condition is treatable by interfering selectively with the natural activity of the CXCR7 receptor and its natural ligands CXCL11 and/or CXCL12.

12. The use of a compound of formula **(I)** as defined in any one of claims 1 to 9 for the manufacture of a medicament for the treatment, prevention or the supportive treatment of a disease or condition related to the activity of CXCR7 selected from dermatological disorders, metabolic diseases, inflammatory diseases, fibrotic diseases, infectious diseases, neurological diseases, cardiovascular diseases, respiratory diseases, gastro-intestinal tract disorders, urological diseases, ophthalmic diseases, stomatological diseases, haematological diseases and oncology, or the mobilisation of stem cells.

13. The use according to claim 12, wherein the wherein the disease or condition related to the activity of CXCR7 is selected from HIV infections, Epstein-Barr Virus infection; Type I and/or Type II diabetes mellitus; conjunctivitis, scleritis, uveitis, rhinosinusitis, Whim syndrome, lupus erythematosus, osteoarthritis, rheumatoid arthritis, synovitis, psoriasis, multiple sclerosis, Crohns disease, inflammatory bowel disease, mixed connective tissue disease, chronic lymphocytic thyroiditis, Graves' disease, graft-versus-host disease, Sjögren's syndrome; dry eye syndrome, glaucoma, age-related macular degeneration; pulmonary arterial hypertension, pulmonary hypoxia, atherosclerosis, myocarditis, heart failure including myocardial infarction, arterial thrombosis, stroke and angiogenesis; chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, asthma; sarcomaincluding osteosarcoma, rhabdomyosarcoma, Kaposi's sarcoma and synovial sarcoma; lipoma including angiolipoma; glioblastoma multiforme, astrocytomas, neuroblastoma; carcinoma

including adenocarcinoma; malignant epithelial and mucoepidermoid neoplasms, thyroid neoplasm, gonadal neoplasms, prostate cancer, breast cancer, melanoma, lung carcinoma, pancreatic carcinoma, colorectal cancer; solid tumors; lymphoma including Birkitt's lymphoma, Hodgkin's lymphoma and non-Hodgkin's lymphoma; multiple myeloma and leukemia; and metastasis.

14. Use of a compound of formula **(I)** as defined in any one of claims 1 to 9, in the manufacture of a medicament for the inhibition of neointima formation; stem cell mobilisation of peripheral blood stem cells and/or mesenchymal stem cells; mobilisation of endothelial or neuronal progenitor cells; or tissue-repair in human or other mammals.

15. The use according to any one of claims 1 to 14, wherein the medicament is in a form suitable for oral, topical, transdermal, injection, buccal, transmucosal, rectal, pulmonary or inhalation administration.

16. The use according to claim 15, wherein the medicament is in the form of a tablet, a dragee, a capsule, a solution, a liquid, a gel, a plaster, a cream, an ointment, a syrup, a slurry, a suspension, a spray, a nebuliser or a suppository.

17. The use according to any one of claims 1 to 16, wherein the medicament is adapted to administer the compound of formula (I) as the sole active pharmaceutical ingredient or in combination with one or more other active pharmaceutical ingredients present in the medicament or in another medicament.